Your session is about to expire
← Back to Search
Nivolumab + Ipilimumab for Melanoma
This trial is testing a new way to treat melanoma that has not spread. Subjects will receive neoadjuvant nivolumab, which is a drug that helps the immune system kill cancer cells. Then, they will have surgery to remove the melanoma. After surgery, subjects will receive up to 1 year of adjuvant nivolumab or ipilimumab plus nivolumab. This will depend on how well the subject responds to the treatment.
- Melanoma Stage III
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2021 Phase 3 trial • 1844 Patients • NCT03068455
Awards & Highlights
Find a Location
Who is running the clinical trial?
- You have already received treatment with drugs that target the immune system, such as anti-PD-1, anti-PD-L1, or other similar medications.You have another type of cancer that is getting worse or needs treatment, except for certain types that are not considered as serious.
- Group 1: Arm C: Adjuvant Combination (Less than Complete Response)
- Group 2: Arm A: Adjuvant Nivolumab (Complete Pathological Response)
- Group 3: Arm B: Adjuvant Nivolumab (Less than Complete Response)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there still opportunities to join this experiment?
"This clinical trial is currently open to participants, with the original posting on January 1st 2020 and a subsequent update made in March 25th 2022. This information can be found via a search of clinicaltrials.gov."
What medical conditions might prompt a doctor to prescribe nivolumab?
"Nivolumab is typically used for patients who have undergone angiogenic therapies, but can also be effective when treating malignant neoplasms, unresectable melanoma, and squamous cell carcinomas."
What is the current enrollment capacity for this clinical trial?
"Affirmative. Information published on clinicaltrials.gov states that this study, which was initially posted in January of 2020, is actively recruiting candidates. At present, 60 individuals need to be enrolled from two distinct sites."
Has the Food and Drug Administration sanctioned nivolumab for therapeutic use?
"Nivolumab was rated 2 on our safety scale, as there is some evidence of the drug's security but no proof demonstrating its efficiency."
Have any other scientific investigations been conducted regarding nivolumab?
"In 2009, nivolumab was first studied at Texas Children's Hospital. Since then, 363 trials have been completed and 764 are in progress, with many of them occurring in Philadelphia."
Share this study with friends